0 CHECKOUT

Apoptosis in Oncology Drug Pipeline Update

  • ID: 1197079
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.

There are today 460 companies plus partners developing 588 apoptotic drugs in 2586 developmental projects in cancer. In addition, there are 13 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 307 drugs. Apoptosis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 389 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 377 out of the 380 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 75 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)